ITMO Santé Publique
ITMO Santé Publique
Date de modification : 05/05/2021 | Version : 1 | ID : 73865
| Général | |
| Identification | |
| Nom détaillé | SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology |
| Sigle ou acronyme | PEDONCOVID |
| Thématiques générales | |
| Domaine médical |
Pediatrics |
| Etude en lien avec la Covid-19 |
Yes |
| Pathologie, précisions | Paediatric oncology |
| Mots-clés | cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19 |
| Responsable(s) scientifique(s) | |
| Nom du responsable | ROUGER-GAUDICHON |
| Prénom | Jérémie |
| Organisme | CHU Caen Normandie |
| Collaborations | |
| Financements | |
| Gouvernance de la base de données | |
| Organisation(s) responsable(s) ou promoteur | CHU Caen Normandie |
| Statut de l’organisation |
Secteur Public |
| Contact(s) supplémentaire(s) | |
| Caractéristiques | |
| Type de base de données | |
| Type de base de données |
Study databases |
| Base de données issues d'enquêtes, précisions |
Cohort study |
| Origine du recrutement des participants |
A selection of health institutions and services |
| Le recrutement dans la base de données s'effectue dans le cadre d'une étude interventionnelle |
No |
| Objectif de la base de données | |
| Objectif principal | Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy. |
| Critères d'inclusion |
Children and legal representatives, or adult patients having received information on the study
AND - Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy AND - Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology OR - Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with: o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. AND o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a crazy-paving appearance, linear condensations with or without peripheral halo (reverse halo sign). |
| Type de population | |
| Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) |
| Population concernée |
Sick population |
| Pathologie | II - Neoplasms |
| Sexe |
Male Woman |
| Champ géographique |
National |
| Collecte | |
| Dates | |
| Taille de la base de données | |
| Taille de la base de données (en nombre d'individus) |
< 500 individuals |
| Données | |
| Activité de la base |
Current data collection |
| Type de données recueillies |
Clinical data Biological data |
| Données cliniques, précisions |
Direct physical measures |
| Existence d’une biothèque |
No |
| Modalités | |
| Pathologie suivies | |
| Valorisation et accès | |
| Valorisation et accès | |
| Accès |
| A PROPOS | CATALOGUE | RESSOURCES | LIENS UTILES
|  Ce site respecte les principes de la charte HONcode. Vérifiez ici. |
8 rue de la Croix Jarry 75013 Paris Tél: 01 44 23 67 47 |
Partenaires - F.A.Q. - Contact - Plan du site - Mentions légales - Administration - PEF-HD - Mis à jour le 15 décembre 2020 - Version 4.10.05
